https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Adecreased antiplatelet prophylaxis (low response, LR/high on-treatment platelet reactivity, HPR) with acetylsalicylic acid (ASA) is associated with an increased risk of thromboembolic events. The prevalence of aLR is frequent with about 20% and atherapeutic regimen is not yet established. The aim of this prospective study was to evaluate the effectiveness of atherapeutic regimen for treatment adaptation when LR/HPR is detected in vascular surgery patients. Overall, 36patients under long-term antiplatelet treatment with 100